A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 [entinostat] in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment With a Non-Steroidal Aromatase Inhibitor.

Trial Profile

A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 [entinostat] in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment With a Non-Steroidal Aromatase Inhibitor.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2015

At a glance

  • Drugs Entinostat (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms ENCORE-301
  • Sponsors Syndax Pharmaceuticals
  • Most Recent Events

    • 12 Dec 2015 Results of sub-group analysis (n=49) presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 03 Dec 2015 According to Syndax media release, the data from this trial will be presented at the 2015 San Antonio Breast Cancer Symposium (SABCS).
    • 01 Dec 2015 According to Syndax media release, etinostat was granted breakthrough therapy designation by the US FDA in advanced HR+ breast cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top